Literature DB >> 15531188

The role of glimepiride in the effective management of Type 2 diabetes.

Stephen N Davis1.   

Abstract

Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions. The effective management of Type 2 diabetes is of vital concern to clinicians. The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention. The goals of pharmacologic therapy are to achieve adequate glycemic control while avoiding hypoglycemia and weight gain and to minimize the risk of future micro- and macrovascular complications. There are a number of available glucose-lowering agents from which to choose. This review focuses on the sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, which are effective, well-tolerated, and well-established drugs, Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, alpha-glucosidase inhibitors, and insulin. The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531188     DOI: 10.1016/j.jdiacomp.2004.07.001

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  14 in total

Review 1.  Are sulfonylureas passé?

Authors:  Jennifer B Green; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

2.  Hydrogen peroxide-induced translocation of glycolipid-anchored (c)AMP-hydrolases to lipid droplets mediates inhibition of lipolysis in rat adipocytes.

Authors:  G Müller; S Wied; C Jung; S Over
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

3.  Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.

Authors:  Panagiotis Boglou; Paschalis Steiropoulos; Nikolaos Papanas; Demosthenes Bouros
Journal:  BMJ Case Rep       Date:  2013-04-16

4.  Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments.

Authors:  Subhadeep Banerjee; Indrani Talukdar; Arnab Banerjee; Arnav Gupta; Advait Balaji; Raviprasad Aduri
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

5.  Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.

Authors:  Kun Ho Yoon; Jeong Ah Shin; Hyuk Sang Kwon; Seung Hwan Lee; Kyung Wan Min; Yu Bae Ahn; Soon Jib Yoo; Kyu Jeung Ahn; Sung Woo Park; Kwan Woo Lee; Yeon Ah Sung; Tae Sun Park; Min Seon Kim; Yong Ki Kim; Moon Suk Nam; Hye Soon Kim; Ie Byung Park; Jong Suk Park; Jeong Taek Woo; Ho Young Son
Journal:  Diabetes Metab J       Date:  2011-02-28       Impact factor: 5.376

6.  Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2.

Authors:  Keiko Arai; Tetsuo Nishikawa; Shin-Ichiro Shirabe; Yoko Matsuzawa; Shigeyuki Ohtsu; Shohei Yuasa; Koich Hirao; Hisao Mori
Journal:  Diabetol Int       Date:  2021-07-11

Review 7.  Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.

Authors:  Sanjay Kalra; A H Aamir; Abbas Raza; A K Das; A K Azad Khan; Dina Shrestha; Md Faisal Qureshi; Md Faruque Pathan; Fatema Jawad; Jyoti Bhattarai; Nikhil Tandon; Noel Somasundaram; Prasad Katulanda; Rakesh Sahay; Sanjib Dhungel; Sarita Bajaj; Subhankar Chowdhury; Sujoy Ghosh; S V Madhu; Tofail Ahmed; Uditha Bulughapitiya
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

Review 8.  Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.

Authors:  J M Amate; T Lopez-Cuadrado; N Almendro; C Bouza; Z Saz-Parkinson; R Rivas-Ruiz; J Gonzalez-Canudas
Journal:  Int J Clin Pract       Date:  2015-02-16       Impact factor: 2.503

9.  Glycemic variability: Clinical implications.

Authors:  Surabhi Venkata Satya Krishna; Sunil K Kota; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2013-07

10.  Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes.

Authors:  Chun-Jun Li; Jing-Yun Zhang; De-Min Yu; Qiu-Mei Zhang
Journal:  Diabetol Metab Syndr       Date:  2014-03-20       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.